- Category: HIV Prevention
- Published on Sunday, 24 March 2013 00:00
- Written by Gregory Fowler
The CCR5 co-receptor blocker maraviroc (Selzentry) did not reduce the risk of developing immune reconstitution inflammatory syndrome (IRIS) after starting antiretroviral therapy (ART), according to study findings presented at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
Some research indicates that maraviroc boosts CD4 T-cell gains and may have anti-inflammatory properties, suggesting it might help control IRIS -- the flare-up of symptoms of certain infections as ART controls HIV and allows CD4 cells to resume fighting existing pathogens in the body.
But as Juan Sierra-Madero from Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City reported at a CROI press conference, his group did not see a difference in occurrence of severe IRIS between people taking or not taking maraviroc, and there was only a very small difference in CD4 recovery in favor of maraviroc.
[Juan Sierra-Maderospeaks at CROI 2013 press conference, Atlanta, March 6, 2013]
J Sierra-Madero, et al. Efficacy and Safety of Maraviroc to Prevent Immune Reconstitution Inflammatory Syndrome in High-risk Subjects Initiating ART: 24-week Results of a Randomized, Placebo-controlled Trial. 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013). Atlanta, March 3-6, 2013. Abstract 182LB.